Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07492680). This is a study registration, not published results. Lead sponsor: Bristol-Myers Squibb. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 254 participants (ESTIMATED). Conditions: Solid Tumors. Interventions: DRUG: Navlimetostat; DRUG: Daraxonrasib; DRUG: Temozolomide; DRUG: Pumitamig; DRUG: Pemetrexed; DRUG: Carboplatin; DRUG: Nab-paclitaxel; DRUG: Gemcitabine; DRUG: Paclitaxel; DRUG: Cisplatin. Primary outcome measures: Part 1: Number of participants who achieve Objective Response (OR) , Up to approximately 2 years; Part 2: Number of participants with adverse events meeting protocol defined dose limiting toxicities (DLTs) criteria , Up to approximately 2 years; Part 2: Number of participants with adverse events (AE) , Up to approximately 2 years; Part 2: Number of participants with Serious AEs (SAEs) , Up to approximately 2 years; Part 2: Number of participants with treatment related AEs , Up to approximately 2 years; Part 2: Number of participants with treatment related SAEs , Up to approximately 2 years; Part 2: Number of participants with AEs leading to study treatment discontinuation , Up to approximately 2 years; Part 2: Number of participants with AEs leading to death , Up to approximately 2 years; Part 2: Number of participants with laboratory abnormalities , Up to approximately 2 years. Brief summary: This is an open-label, multicenter Phase 2 study evaluating Navlimetostat (BMS-986504) in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which Navlimetostat (BMS-986504) is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of Navlimetostat (BMS-986504) alone and in combination regimens.